Industry news

Share this article:
The FDA, in partnership with Duke University, announced the executive board for its Clinical Trials Transformation Initiative. The board will be co-chaired by Duke vice chancellor for clinical research Dr. Robert Califf and Dr. Rachel Behrman, director of the Office of Critical Path Programs at FDA. Industry representation on the board includes: Susan Alpert, SVP and chief quality and regulatory officer at Medtronic; Glenn Gormley, SVP, global clinical development and medical affairs, Novartis Pharmaceuticals; and Jay Siegel, group president, R&D, biotechnology, immunology and oncology at Johnson & Johnson. 
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.